Take the CPNP poll

November 2008: How has the earlier FDA warning and recent ISMP quarterly safety data regarding reports of serious injury impacted your use of varenicline for tobacco cessation (Check all that apply)?
	A. No impact, we still consider it a first line option B. Slight alteration, first line option for patients without seizure history or psychiatric illness C. Patients are requesting to use other agents (bupropion or nicotine replacement therapy) first D. There is an increased number of patients discontinuing varenicline, on their own or under supervision E. Use of varenicline is restricted to failure of most other treatment options F. No impact, we rarely use varenicline anyway

October 2008: Has the current economic crisis influenced your pharmacotherapeutic recommendations (Check all that apply)?
	A. No change, I am recommending the same as I did before (59, 64.1%) B. I am recommending more generic psychiatric medications than before (14, 15.2%) C. I am having to make more therapeutic substitutions for psychiatric medications (6, 6.5%) D. I am having to make more therapeutic substitutions for both psychiatric and chronic medications (e.g. hypertension) (11, 12.0%) E. I am making fewer pharmacotherapeutic recommendations and recommending a greater number of non-pharmacologic treatments or lifestyle modifications (2, 2.2%) F. Does not apply to my practice (15, 16.3%)
September 2008: Psychiatric pharmacists are playing an increasingly larger role in the care of patients with mental illness in all settings. While some locations are progressive allowing collaborative practice agreements, prescriptive authority including controlled substance prescribing other locations lag much further behind.
In your opinion which of the following is the most influential resource for promoting/maintaining an expanded scope of pharmacy practice? (Check all that apply)
	A. Enhancing the visibility of clinical pharmacists' activities to the general public (i.e. local/national news campaigns) (69, 61.6%) B. Increasing participation with organizations such as NAMI (35, 31.2%) C. Lobbying efforts at the local, state and national levels (47, 42.0%) D. Active participation in interdisciplinary care teams (86, 76.8%) E. Operating a medication therapy management (MTM) or other pharmacist run clinic (58, 51.8%) F. Participating in initiatives with national organizations such as APA, AMA, etc. (30, 26.8%) G. Building interdisciplinary experiences for pharmacy, medical, nursing, psychology and social work students, residents and fellows (60, 53.6%) H. Research collaborations with various disciplines (physicians, nursing, psychologists, social workers, dieticians, etc) (37, 33.0%) I. Fostering an understanding of clinical pharmacist activities and expertise by speaking at various engagements (i.e. CE programs, conferences, health fairs, etc.) (56, 50.0%)
August 2008: Would you tell us about your involvement with NAMI by answering the following two questions:
Tell us about your involvement with NAMI, National Alliance on Mental Illness. What has been your level of involvement in NAMI during the past 12 months? (Check All that Apply)
	A. Not at all (10, 16.9%) B. Not at all, but interested (20, 33.9%) C. Member of local chapter as consumer / family member (2, 3.4%) D. Member of local chapter as a professional (13, 22.0%) E. On the Board of Directors (local level, state or national?) (3, 5.1%) F. Involved at a state level (4, 6.8%) G. Involved at a national level (2, 3.4%) H. NAMI Walk (at CPNP Annual Meeting) (15, 25.4%) I. NAMI Walk (outside of CPNP's walk) (11, 18.6%) J. Consumer education provider at local, state or national level (16, 27.1%) K. Attended NAMI Convention (6, 10.2%) L. Other involvement (4, 6.8%)
What is your average monthly commitment to NAMI? (Choose One)
	A. Average 0-2 hours / month on NAMI activities (53, 86.9%) B. Average 3-5 hours / month on NAMI activities (7, 11.5%) C. Average 6-8 hours / month on NAMI activities (1, 1.6%) D. Average 9-10 hours / month on NAMI activities (0, 0.0%) E. Average >10 hours / month on NAMI activities (0, 0.0%)
July 2008: With a growing number of 'cleaner' isomeric compounds and active metabolites being introduced into the market (i.e., citalopram-escitalopran, venlafaxine-desvenlafaxine, etc.), differentiating between treatment options is becoming increasingly complex. Many factors play into the decision of which is the preferred pharmacotherapeutic treatment option. In your opinion which TWO factors are the most influential when deciding which agent to have on formulary or recommend for patient use?
	A. Efficacy in Active Comparator Trials (51, 47.7%) B. Efficacy in Placebo Controlled Trials (12, 11.2%) C. Safety and Tolerability Data as summarized in the full prescribing information (3, 2.8%) D. Safety and Tolerabilty Data described individually in the published clinical trials (33, 30.8%) E. Cost utility and effectiveness (78, 72.9%) F. Simplicity of dosing regimen (i.e., once daily vs. multiple times daily) (26, 24.3%) G. Availability of oral formulation corresponding to optimal dosage regimen (5, 4.7%)
June 2008: Emerging literature suggests that folate deficiency may enhance the risk of depression and result in lack of response to antidepressant medications. How has this information influenced the treatment of depressed patients in your practice setting?
	A. No change in the treatment of our patients. (2, 14.3%) B. Increased awareness of the deficiency leading to additional monitoring in some refractory patients. (5, 35.7%) C. Discussion about potential folate deficiency in some refractory patients, treatment initiated in one or two cases. (4, 28.6%) D. Augmentation with folic acid or L methyl folate is being recommended and widely used in our depressed patients. (3, 21.4%)
May 2008: With the media drawing attention to medications that may "increase suicidality" (the most recent being montelukast in late March 2008), changes in prescribing habits and medication usage are expected. In your opinion what role do you see suicidality playing in adverse effect monitoring during the next 1-3 years?
	A. No impact on current practice (8, 7.8%) B. Required reporting of suicidality in clinical trials of psychiatric medications (68, 66.0%) C. Required post marketing surveillance for all new medications (69, 67.0%) D. Increased number of trials in children/adolescents to screen for suicidal thinking/behavior (32, 31.1%) E. Decrease in number of prescriptions written for children/adolescents due to risk of suicidality (43, 41.7%)
April 2008: Health-care providers often have different views on the role of the clinical psychiatric or neurologic pharmacist. How do your fellow health-care providers (e.g. doctors, nurses, psychologist, etc..) see the role of the psychiatric or neurologic pharmacist in your practice setting?
	A. Clinical consultant (99, 79.8%) B. Mid-level practitioner (27, 21.8%) C. Collaborative researcher (29, 23.4%) D. Drug information source (91, 73.4%) E. Medication reconciliation person (34, 27.4%) F. Does not apply to my practice. (8, 6.5%)
March 2008: Keeping up with the scientific literature can be challenging. On average how many journal articles do you read per month?
	A. 1-2 (40, 18.5%) B. 3-5 (50, 23.1%) C. 6-8 (56, 25.9%) D. 9-12 (41, 19.0%) E. more than 12 (29, 13.4%) F. I do not keep up with the current literature (0, 0.0%)
February 2008: In early January, FRONTLINE aired a Program The Medicated Child, talking about the increased incidence in prescribing drugs for troubled children. In particular there has been a huge increase in the diagnosis of bipolar disorder in children (defined as young as 4 years old) over the past 7 years. With all the press about the rise of bipolar disorder diagnoses in children, do you believe it exists?
	A. Yes. (40, 21.4%) B. No. (50, 26.7%) C. I believe it exists in children but feel it is often over-diagnosed. (56, 29.9%) D. More research needs to be done in this area before we can determine this. (41, 21.9%)
January 2008: If you belong to other pharmacy related organizations/associations besides CPNP, what value do you receive from these additional memberships? (Check all that apply)
	A. Keeps me updated on non-psychiatry/neurology related pharmacy issues. (82, 69.5%) B. Allows me to obtain additional CE credits. (30, 25.4%) C. Important for networking with colleagues outside of CPNP. (70, 59.3%) D. Looks good on my CV to have multiple professional memberships. (36, 30.5%) E. I do not belong to other pharmacy related organizations besides CPNP. (8, 6.8%) F. Other (email info@cpnp.org with an explanation) (9, 7.6%)

College of Psychiatric and Neurologic Pharmacists

Member Center

Membership Brochure

Take the CPNP poll

November 2008: How has the earlier FDA warning and recent ISMP quarterly safety data regarding reports of serious injury impacted your use of varenicline for tobacco cessation (Check all that apply)?

October 2008: Has the current economic crisis influenced your pharmacotherapeutic recommendations (Check all that apply)?

In your opinion which of the following is the most influential resource for promoting/maintaining an expanded scope of pharmacy practice? (Check all that apply)

August 2008: Would you tell us about your involvement with NAMI by answering the following two questions:

Tell us about your involvement with NAMI, National Alliance on Mental Illness. What has been your level of involvement in NAMI during the past 12 months? (Check All that Apply)

What is your average monthly commitment to NAMI? (Choose One)

June 2008: Emerging literature suggests that folate deficiency may enhance the risk of depression and result in lack of response to antidepressant medications. How has this information influenced the treatment of depressed patients in your practice setting?

April 2008: Health-care providers often have different views on the role of the clinical psychiatric or neurologic pharmacist. How do your fellow health-care providers (e.g. doctors, nurses, psychologist, etc..) see the role of the psychiatric or neurologic pharmacist in your practice setting?

March 2008: Keeping up with the scientific literature can be challenging. On average how many journal articles do you read per month?

January 2008: If you belong to other pharmacy related organizations/associations besides CPNP, what value do you receive from these additional memberships?